Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe

SmartfIRE study is evaluating THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter’s potential to enable safe and simple procedures with the ability to deliver both radiofrequency (RF)

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i today announced that enrollment is complete in the SmartfIRE study designed to evaluate the safety and efficacy of its investigational THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter and investigational TRUPULSE™ Generator for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (AFib) during standard electrophysiology mapping and ablation procedures.[i] The catheter and the generator are fully integrated with the CARTO™ 3 Advanced 3D Imaging System.

SmartfIRE is a pivotal, prospective, multi-center, single-arm study evaluating Biosense Webster’s dual energy pulsed field (PF) and radiofrequency (RF) ablation system. Since the study’s commencement in February 2023, the trial has enrolled 149 patients with paroxysmal AFib across nine centers in Europe. Patients will be assessed for 12 months for safety and efficacy.1

“Biosense Webster’s dual energy ablation system has the potential to enable electrophysiologists to eliminate the need to exchange catheters and allow them to seamlessly switch the energy source, whether RF or PF, based on patient needs,” said Gediminas Račkauskas, M.D., Ph.D., Cardiac Electrophysiologist, Vilnius University Hospital Santaros Clinics, Lithuania.ii “Together with the CARTO™ 3 Mapping System that enables real-time catheter visualization, this system has the potential to drive enhanced safety, efficiency, and effectiveness of ablation procedures, while allowing doctors to utilize a familiar workflow.”

The THERMOCOOL SMARTTOUCH™ SF radiofrequency catheter has been available in Europe since 2016. It is the most commonly used ablation catheter in the world for RF ablation, and many electrophysiologists have a high degree of familiarity and confidence in using this tool for highly precise cardiac ablation procedures.[ii] The THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter with Contact Force Sensing Capability is an investigational steerable, multi-electrode luminal, irrigated catheter for PF and RF ablation. The investigational TRUPULSEGenerator provides both the RF energy and the novel uni-polar, bi-phasic pulse field (PF) energy to the catheter through the toggling of the two energy sources on the generator monitor.[iii] The THERMOCOOL SMARTTOUCH™ SF Catheter is to be used in this investigational study with the TRUPULSE™ Generator, to transmit the PF or RF energy to the catheter tip electrode for cardiac ablation. The catheter and the generator are integrated with the CARTO™ 3 System. The TRUPULSE Generator is an investigational device and is not available for sale in the US or in Europe.

“Given the strong trust and familiarity physicians have with the THERMOCOOL SMARTTOUCH SF catheter and also industry interest in the potential of PFA, we saw a high level of excitement for participation in the SmartfIRE clinical trial,” said Jasmina Brooks, President, Biosense Webster, Inc. “This study will contribute to a growing body of evidence being developed by Biosense Webster to support the use of PFA as an additional option for AFib treatment, complementing our best-in-class RF ablation catheter portfolio.”

Catheter ablation is a minimally-invasive procedure performed by an electrophysiologist to treat heart rhythm disorders, including AFib, by interrupting irregular electrical pathways in the heart by delivering either heat (RF ablation) or cold (Cryoablation).[iv] PFA could represent a new approach to treating AFib, utilizing a controlled electric field to selectively ablate cardiac tissue that causes the irregular heart beat through a process called irreversible electroporation (IRE). Because the pulsed field energy is minimally thermal , IRE offers the potential to reduce the risk of damage to surrounding tissues including esophageal, pulmonary vein, and phrenic nerve injury.[v]

AFib is the most common type of cardiac arrhythmia and impacts nearly 37.5 million people worldwide,[vi] and 11 million people in Europe alone.[vii] Today, about 1 in 4 adults over the age of 40 are at risk for developing AFib.[viii] Despite these projections, many people are unfamiliar with AFib symptoms, available treatment options and the importance of early treatment to avoid disease progression.[ix]

In March 2023, Biosense Webster announced the first patients treated in the SmartfIRE study. The THERMOCOOL SMARTTOUCH™ SF Dual Energy Catheter and the TRUPULSE™ Generator are under development and not available for sale in any region of the world. To learn more about the SmartfIRE study and our approach to PFA, visit

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy